"If not dead, not healthy": Niacin full results in HPS2-THRIVE aired at ACC

Regarding the primary end point, the combination of coronary death, nonfatal MI, stroke, or coronary revascularization occurred in 15.0% of patients in the control arm and 14.5% of patients in the niacin/laropiprant arm, a difference that was not statistically significant. Equally important, the researchers also documented a significantly increased risk of adverse events with niacin/laropiprant, with approximately 30 adverse events per 1000 treated patients.
Source: theHeart.org - Category: Cardiology Source Type: news